Brian K Kobilka

Stanford, CA, United States of America

Brian K Kobilka

This inventor holds 44 USPTO granted patents and 18 published patent applications and 12 EPO patents, primarily in GPCR Research. Top assignees: Leland Stanford Junior University, Vrije Universiteit Brussel, Vib Vzw. Active years: 1999-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian K Kobilka. Retrieved from https://idiyas.com/inventor/brian-k-kobilka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 

% Patents Active = 86.4

 

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 125(Granted Patents)


Location History:

  • Palo Alto, CA (US) (1999 - 2022)
  • Stanford, CA (US) (2023)
  • Ithaca, NY (US) (2023)

Company Filing History:


Years Active: 1999-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
GPCR
Ligand Efficacy
Conformational States
Receptor Modulators
Binding Domains
Crystallization Methods
Transmembrane Receptors
Fluorescence Energy Transfer
Amphiphilic Compounds
Synthetic Amphiphiles
Eukaryotic Expression System
Monoclonal Antibody
44 patents (USPTO):Explore Patents

Title: Innovations in GPCR Research by Brian K Kobilka

Introduction

Brian K Kobilka, based in Stanford, CA, is a prominent inventor in the field of structural biology, particularly known for his groundbreaking work on G-protein-coupled receptors (GPCRs). With an impressive portfolio of 43 patents, Kobilka has made significant contributions to our understanding of GPCR signaling, which plays a crucial role in various physiological processes and disease states.

Latest Patents

Among his most recent innovations are two notable patents. The first patent focuses on protein binding domains that stabilize functional conformational states of GPCRs. This invention advances the field by providing tools for the structural and functional characterization of GPCRs, enabling researchers to explore their interactions with both natural and synthetic ligands more effectively. Moreover, it highlights the potential for therapeutic applications in GPCR-related diseases.

The second patent introduces methods for quantifying ligand efficacy in GPCRs using single-molecule fluorescence resonance energy transfer (smFRET) imaging. This technique provides a novel approach to understanding the molecular efficacy of ligands, paving the way for enhanced drug discovery efforts targeting GPCRs.

Career Highlights

Brian Kobilka has made significant strides in the scientific community through his work at Leland Stanford Junior University, where he has advanced the field of GPCR research. His innovative contributions have helped to elucidate the complex mechanisms of GPCR signaling, a critical area of study in pharmacology and therapeutic development.

Collaborations

Throughout his career, Kobilka has collaborated with notable scientists, including Jan Steyaert and Toon Laeremans, who share his dedication to advancing the understanding of GPCR biology. These collaborations have led to innovative approaches in studying GPCRs and their interactions, resulting in valuable insights and advancements in the field.

Conclusion

Brian K Kobilka's contributions to the field of GPCR research have not only expanded our comprehension of these vital receptors but also offered new avenues for therapeutic exploration. His extensive patent portfolio reflects his commitment to innovation and excellence, positioning him as a key figure in modern biomedical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…